• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Hepion Pharmaceuticals Inc.

    4/28/26 5:06:07 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HEPA alert in real time by email
    DEFA14A 1 formdefa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 14A Information

     

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

     

    (Amendment No. )

     

    Filed by the Registrant ☒

     

    Filed by a party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement

     

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐ Definitive Proxy Statement

     

    ☒ Definitive Additional Materials

     

    ☐ Soliciting Material under § 240.14a-12

     

    Hepion Pharmaceuticals, Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required

     

    ☐ Fee paid previously with preliminary materials.

     

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

     

     

     

     
     

     

    NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS

     

    The Annual Meeting of Stockholders of Hepion Pharmaceuticals, Inc. will be held on June 17, 2026, at 9:00 a.m. local time at

    Sheppard Mullin Richter & Hampton, 30 Rockefeller Plaza, New York, NY 10112

     

    PROXY STATEMENT AND 2025 ANNUAL REPORT ON FORM 10-K

    ARE AVAILABLE AT:

     

    https://annualgeneralmeetings.com/hepa2026

     

    Dear Stockholder:

     

    The Annual Meeting of Stockholders of Hepion Pharmaceuticals, Inc. has been called to consider and act upon the following matters:

     

    Proposal 1: Election of five (5) Directors;
       
    Proposal 2: Ratification of Grassi & Co., CPAs, P.C. as our independent registered public accounting firm for fiscal year ending December 31, 2026; and
       
    Proposal 3: To consider and act upon a proposal to approve an amendment to the Company’s 2023 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 8,000,000 from 200,000

     

    Our Board of Directors recommends a vote “FOR” all nominees listed in proposal 1 and “FOR” proposals 2 and 3.

     

    You are receiving this communication because you hold shares in the company named above. Complete proxy materials, including the proxy card, are available to you on-line at https://annualgeneralmeetings.com/hepa2026 or upon your request by e-mail or first-class mail. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    This is not a ballot. You cannot use this notice to vote your shares. You may vote on-line, by mail or in person. If you wish to vote on-line, you will need your “Control Number” (which can be found in the bottom right hand corner of this notice) and the web address, all of which will be included with or on the proxy card located on the Internet website stated above or mailed to you at your request. No other personal information will be required in order to vote in this manner. If you wish to vote by mail, simply print out the proxy card located on the Internet website stated above, mark the proxy card accordingly, sign and return it to us at the address indicated on the proxy card. If you wish to vote in person at the Annual Meeting of Stockhold ers, simply check the box on the proxy card that you plan to attend. Your proxy card will not be used if you vote in person. Please check the meeting materials for any special requirements for meeting attendance and how to obtain directions to the meeting.

     

    Control Number:                                   

     

     
     

     

    Important Notice Regarding the Availability of Proxy Materials

     

    for the Stockholder Meeting To Be Held on June 17, 2026:

     

    (1)This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    (2)The Proxy Statement and 2025 Annual Report on Form 10-K are available at https://annualgeneralmeetings.com/hepa2026

     

    (3)If you want to receive a paper or e-mail copy of these documents, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed below on or before May 28, 2026 to facilitate timely delivery.

     

    To request a paper copy of these items:

     

    ●Call our toll-free number – 1-800-785-3033; or
       
    ●Visit our website at https://annualgeneralmeetings.com/hepa2026; or
       
    ●Send us an e-mail at cs@pacificstocktransfer.com

     

    Please clearly identify the items you are requesting; Hepion Pharmaceuticals, Inc., and your name along with the Control Number located in the lower right hand corner of this notice and the name and address to which the materials should be mailed.

     

      By Order of the Board of Directors
       
      /s/ Vincent LoPriore
      Executive Chairman of the Board of Directors

     

    Control Number:                                   

     

     
     

     

     

     
     

     

     

     

    Get the next $HEPA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HEPA

    DatePrice TargetRatingAnalyst
    2/28/2022$3.50Overweight
    Cantor Fitzgerald
    More analyst ratings

    $HEPA
    SEC Filings

    View All

    SEC Form 10-Q filed by Hepion Pharmaceuticals Inc.

    10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

    5/14/26 4:35:01 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Hepion Pharmaceuticals Inc.

    DEFA14A - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

    4/28/26 5:06:07 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Hepion Pharmaceuticals Inc.

    DEF 14A - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

    4/28/26 5:01:47 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma

    Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion's strategic shift to advancing clinically proven liquid biopsy tests under new leadership MORRISTOWN, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a precision diagnostics company, today announced that it has in-licensed from Cirna Diagnostics LLC, a novel biomarker assay that detects mutant circulating tumor RNA (ctRNA) to facilitate early diagnosis of hepatocellular carcinoma (HCC) in high-risk patients (cirrhosis). Most cases of liver cancer (75-90%) are HCC, and HCC is the sixth most common cancer w

    3/3/26 7:35:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

    MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that it has successfully completed the process of transitioning to the OTCQB Venture Market. The Company's common stock begins trading on the OTCQB Venture Market today, June 25, 2025 with the trading symbol, HEPA. About Hepion Pharmaceuticals Hepion is a clinical stage biopharmaceutical company that is developing and commercializing diagnost

    6/25/25 8:30:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer

    MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that Dr. Kaouthar Lbiati has been named as interim Chief Executive Officer, effective June 16, 2025. Dr. Lbiati is replacing John Brancaccio, who is retiring for personal reasons. Dr. Lbiati's appointment signals a new chapter for Hepion—one focused on strategic renewal, value creation, and diagnostic innovation in areas of significant unmet clin

    6/16/25 8:30:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Purcell Michael J. bought $50,000 worth of shares (1,250,000 units at $0.04) (SEC Form 4)

    4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    4/27/26 5:33:08 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman Lopriore Vincent S bought $250,000 worth of shares (6,250,000 units at $0.04) (SEC Form 4)

    4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    4/27/26 6:24:56 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interim CEO Stetz Gary S. bought $50,000 worth of shares (1,250,000 units at $0.04) (SEC Form 4)

    4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    4/27/26 6:24:44 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Hepion Pharmaceuticals with a new price target

    Cantor Fitzgerald initiated coverage of Hepion Pharmaceuticals with a rating of Overweight and set a new price target of $3.50

    2/28/22 8:01:07 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Lopriore Chase claimed ownership of 1,250,000 shares (SEC Form 3)

    3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    5/26/26 5:00:17 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Purcell Michael J. bought $50,000 worth of shares (1,250,000 units at $0.04) (SEC Form 4)

    4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    4/27/26 5:33:08 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman Lopriore Vincent S bought $250,000 worth of shares (6,250,000 units at $0.04) (SEC Form 4)

    4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    4/27/26 6:24:56 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    Leadership Updates

    Live Leadership Updates

    View All

    Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

    EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company's Board of Directors, effective March 5, 2024. Mr. Purcell has more than 37 years of professional experience with Deloitte & Touche LLP, serving as a consultant from 2015 to 2017 and an Audit Partner from 1979 until 2015. Mr. Purcell also currently serves as a financial advisor to several emerging growth companies. Mr. Purcell is a certified p

    3/6/24 8:30:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theralase(R) Announces Appointment of New Independent Director

    TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc. Dr. Lbiati received her Doctor of Medicine from Rabat, Morocco's Mohammed V University and a post-doctorate in clinical oncology from Gustave Roussy Institute in Paris, which is a premier European cancer center and one o

    6/6/23 7:00:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati

    EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and hepatocellular carcinoma ("HCC"), today announced the appointments of Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its Board of Directors, effective immediately. "We are thrilled to welcome individuals of this caliber to our Board," said Hepion's Chairman, Gary S. Jacob, Ph.D. "Mr. Reddi and Dr. Lbiati have a remarkable wealth of experience across all aspects of drug development, from clinical research to med

    6/28/22 8:30:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    Financials

    Live finance-specific insights

    View All

    Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

    - Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test - "These findings presented today at AASLD The Liver Meeting® confirm that rencofilstat's novel mechanism of action represents a fresh approach to the treatment of severe liver disease." (Patrick Mayo, PhD, Hepion's Senior VP, Clinical Pharmacology & Analytics) EDISON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the t

    11/13/23 4:05:00 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat

    EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that it expects to release additional efficacy data from the Phase 2 ALTITUDE-NASH clinical trial of its lead drug, rencofilstat, after market close on Monday, November 13, 2023. The data release will follow a late-breaker poster presentation by Hepion's Senior Vice President, Clinical Pharmacology, Patrick Mayo, PhD, at the

    11/10/23 8:50:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hepion Pharmaceuticals' Phase 2 'ALTITUDE-NASH' Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

    - Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat's direct antifibrotic mode of action; increases confidence for reductions in fibrosis in ongoing Phase 2b ‘ASCEND-NASH' paired biopsy trial - EDISON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence ("AI")-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced positive topline results from its recentl

    5/22/23 7:00:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hepion Pharmaceuticals Inc.

    SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

    11/14/24 4:07:59 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Hepion Pharmaceuticals Inc.

    SC 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

    2/14/24 3:38:57 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Hepion Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

    2/14/22 6:05:01 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care